Yoda Therapeutics

Executive Summary

Yoda Therapeutics (now Dasher Neuroscience) is a Taiwan-based biotech leveraging an AI-driven platform to discover disease-modifying therapies for CNS disorders. Founded in 2020, the company integrates multi-omics data, molecular modeling, and predictive analytics to accelerate target identification and candidate optimization. Its pipeline targets neurodegenerative diseases such as Multiple System Atrophy (MSA), Parkinson's disease, Alzheimer's disease, and psychiatric disorders like schizophrenia. Currently in Phase 2, the company aims to validate its AI approach in clinical settings. With a focus on high-unmet-need indications and a differentiated technology, Yoda Therapeutics represents a compelling opportunity in the AI-powered drug discovery space.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead MSA candidate40% success
• Q2 2026Potential licensing or partnership deal for AI platform50% success
• Q3 2026Series B funding announcement70% success